TAHO is a specialty pharma focus on identifying, and developing new products that offer better therapeutic options to patient populations that may be under served. By utilizing company’s technology platform, it offers service niches in drug delivery. TAHO’s transdermal delivery platform allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. It transform the patient care by: . Continuous delivery, safe, reliable, and pain-free application . Improved convenience, tolerability, and dosing . Flexible drug administration TAHO’s transmucosal delivery system, delivery the drug as a thin film, an evolution from tablets or capsules. It is a better patient care with: . Convenient dosing, no water needed . No risk of choking . Taste masking Let TAHO be your partner for innovative solutions and diverse your product pipeline
Forendo Pharma is a drug development company aiming for novel treatment solutions for endometriosis patients, by using tissue-specific hormone inhibitors, to rebalance local estrogen metabolism. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels. The company was founded in 2013 by leading academic endocrinology professionals and Finnish drug development pioneers. Forendo is supported by strong investors with broad international contacts: Novo Seeds, Karolinska Development, Novartis Venture Fund, Merck Ventures and Innovestor. T he company pipeline includes HSD17B1 inhibitor (preclinical) for the treatment of endometriosis; Dual HSD inhibitor (discovery) for the treatment of endometriosis, with potential for other endocrinological diseases; Fispemifene (phase 2), novel SERM for the treatment of male urological conditions.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients. BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential: Acute myeloid leukaemia (AML); Advanced non-small-cell lung cancer (NSCLC); Triple negative breast cancer (TNBC) The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules. BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic and diagnostic agents for the treatment and monitoring of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. The company currently has two candidates in development. One targeting HPV for cervical cancer and one against Survivin/IAP for a range of solid tumours.
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature